{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:15:28Z","timestamp":1758816928472},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T00:00:00Z","timestamp":1358380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Drug Investigation"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40261-012-0049-6","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T15:47:56Z","timestamp":1358351276000},"page":"123-131","source":"Crossref","is-referenced-by-count":14,"title":["Effect of Concomitant Administration of Trospium Chloride Extended Release on the Steady-State Pharmacokinetics of Metformin in Healthy Adults"],"prefix":"10.1007","volume":"33","author":[{"given":"Michael G.","family":"Oefelein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Bhasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,17]]},"reference":[{"issue":"6","key":"49_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"4 Suppl","key":"49_CR2","first-page":"S90","volume":"15","author":"E Onukwugha","year":"2009","unstructured":"Onukwugha E, Zuckerman IH, McNally D, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009;15(4 Suppl):S90\u20137.","journal-title":"Am J Manag Care"},{"issue":"1","key":"49_CR3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afi205","volume":"35","author":"CW McGrother","year":"2006","unstructured":"McGrother CW, Donaldson MM, Hayward T, et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing. 2006;35(1):16\u201324.","journal-title":"Age Ageing"},{"issue":"6","key":"49_CR4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1471-0528.2004.00137.x","volume":"111","author":"PM Teleman","year":"2004","unstructured":"Teleman PM, Lidfeldt J, Nerbrand C, et al. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women. BJOG. 2004;111(6):600\u20134.","journal-title":"BJOG"},{"issue":"10","key":"49_CR5","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc07-0262","volume":"30","author":"JM Lawrence","year":"2007","unstructured":"Lawrence JM, Lukacz ES, Liu IL, et al. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes Care. 2007;30(10):2536\u201341.","journal-title":"Diabetes Care"},{"issue":"1","key":"49_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1464-410X.2003.04271.x","volume":"92","author":"HM Dallosso","year":"2003","unstructured":"Dallosso HM, McGrother CW, Matthews RJ, et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 2003;92(1):69\u201377.","journal-title":"BJU Int"},{"key":"49_CR7","volume-title":"US prescribing information","author":"Sanctura XR (trospium chloride extended release capsules)","year":"2008","unstructured":"Sanctura XR (trospium chloride extended release capsules). US prescribing information. Irvine: Allergan, Inc.; 2008."},{"issue":"7","key":"49_CR8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","volume":"44","author":"O Doroshyenko","year":"2005","unstructured":"Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701\u201320.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"49_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5414\/CPP38223","volume":"38","author":"I Fusgen","year":"2000","unstructured":"Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000;38(5):223\u201334.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"49_CR10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0091270006289481","volume":"46","author":"B Sandage","year":"2006","unstructured":"Sandage B, Sabounjian L, Shipley J, et al. Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. J Clin Pharmacol. 2006;46(7):776\u201384.","journal-title":"J Clin Pharmacol"},{"key":"49_CR11","unstructured":"Glucophage (metformin hydrochloride) tablets; Glucophage XR (metformin hydrochloride) extended-release tablets. US prescribing information. Princeton: Bristol-Myers Squibb Company; 2009."},{"issue":"Suppl 1","key":"49_CR12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1055\/s-0029-1240928","volume":"42","author":"B Paulweber","year":"2010","unstructured":"Paulweber B, Valensi P, Lindstrom J, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010;42(Suppl 1):S3\u201336.","journal-title":"Horm Metab Res"},{"issue":"Suppl 1","key":"49_CR13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","volume":"33","author":"American Diabetes Association","year":"2010","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20132010. Diabetes Care. 2010;33(Suppl 1):S11\u201361.","journal-title":"Diabetes Care"},{"issue":"7","key":"49_CR14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4158\/EP.14.7.933","volume":"14","author":"AJ Garber","year":"2008","unstructured":"Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933\u201346.","journal-title":"Endocr Pract"},{"issue":"5","key":"49_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1464-5491.2007.02157.x","volume":"24","author":"KG Alberti","year":"2007","unstructured":"Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24(5):451\u201363.","journal-title":"Diabet Med"},{"issue":"1","key":"49_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","volume":"6","author":"A Lee","year":"1998","unstructured":"Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6(1):47\u201353.","journal-title":"Obes Res"},{"issue":"1","key":"49_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","volume":"4","author":"A Gokcel","year":"2002","unstructured":"Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002;4(1):49\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"49_CR18","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2006-0241","volume":"91","author":"S Srinivasan","year":"2006","unstructured":"Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91(6):2074\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"49_CR19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/meta.2001.24192","volume":"50","author":"CJ Glueck","year":"2001","unstructured":"Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50(7):856\u201361.","journal-title":"Metabolism"},{"key":"49_CR20","unstructured":"Herper M. America\u2019s most popular drugs [online]. 2010; Available from URL: http:\/\/www.forbes.com\/2010\/05\/11\/narcotic-painkiller-vicodin-business-healthcare-popular-drugs.html . [Accessed September 3, 2011]."},{"issue":"12","key":"49_CR21","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1007\/s00125-005-0026-1","volume":"48","author":"A Holstein","year":"2005","unstructured":"Holstein A, Stumvoll M. Contraindications can damage your health\u2013is metformin a case in point? Diabetologia. 2005;48(12):2454\u20139.","journal-title":"Diabetologia"},{"issue":"5","key":"49_CR22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","volume":"30","author":"AJ Scheen","year":"1996","unstructured":"Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"49_CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00210-010-0590-x","volume":"383","author":"B Wenge","year":"2011","unstructured":"Wenge B, Geyer J, Bonisch H. Oxybutynin and trospium are substrates of the human organic cation transporters. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(2):203\u20138.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"49_CR24","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/dmd.107.015495","volume":"35","author":"M Zhou","year":"2007","unstructured":"Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35(10):1956\u201362.","journal-title":"Drug Metab Dispos"},{"key":"49_CR25","doi-asserted-by":"crossref","unstructured":"Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007;178(3 Pt 1):978\u201383; discussion 83\u20134.","DOI":"10.1016\/j.juro.2007.05.058"},{"key":"49_CR26","unstructured":"Allergan, Inc. Data on file."},{"key":"49_CR27","unstructured":"Coca-Perraillon M. Local and Global Optimal Propensity Score Matching, Paper 185-2007. Presented at the SAS Global Forum 2007, Orlando, Florida, USA; 2007; Paper 185-2007."},{"key":"49_CR28","unstructured":"US Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007 [online]. 2008; Available from URL: http:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/ndfs_2007.pdf [Accessed July 9, 2011]."},{"issue":"13","key":"49_CR29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","volume":"295","author":"CL Ogden","year":"2006","unstructured":"Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999\u20132004. JAMA. 2006;295(13):1549\u201355.","journal-title":"JAMA"},{"key":"49_CR30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2458-8-200","volume":"8","author":"A Berghofer","year":"2008","unstructured":"Berghofer A, Pischon T, Reinhold T, et al. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200.","journal-title":"BMC Public Health"},{"issue":"10","key":"49_CR31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jama.286.10.1195","volume":"286","author":"AH Mokdad","year":"2001","unstructured":"Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195\u2013200.","journal-title":"JAMA"},{"issue":"5","key":"49_CR32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047\u201353.","journal-title":"Diabetes Care"},{"issue":"4","key":"49_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.20787","volume":"29","author":"MB Chancellor","year":"2010","unstructured":"Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn. 2010;29(4):551\u20134.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"49_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/0091270009345498","volume":"50","author":"N Silver","year":"2010","unstructured":"Silver N, Sandage B, Sabounjian L, et al. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. J Clin Pharmacol. 2010;50(2):143\u201350.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0049-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0049-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0049-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T19:46:08Z","timestamp":1714851968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0049-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,17]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0049-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,17]]}}}